HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.

AbstractPURPOSE:
Individuals with metastatic melanoma have a poor prognosis. Many human melanomas are auxotrophic for arginine, and arginine is not an essential amino acid in humans. We hypothesized that this auxotrophy may be therapeutically exploited. A novel amino acid-degrading enzyme (arginine deiminase) conjugated to polyethylene glycol (ADI-SS PEG 20,000 mw) was used to lower plasma arginine in individuals with metastatic melanoma.
PATIENTS AND METHODS:
Two cohort dose-escalation studies were performed. A phase I study in the United States enrolled 15 patients, and a phase I to II study in Italy enrolled 24 patients. The Italian patients also received two subsequent cycles of treatment, each consisting of four once-weekly injections of 160 U/m2. The goals of these studies were to determine pharmacokinetics (PK), pharmacodynamics (PD), safety, and the antitumor activity of ADI-SS PEG 20,000 mw.
RESULTS:
PK and PD studies indicated that a dose of 160 U/m2 lowered plasma arginine from a resting level of approximately 130 micromol/L to less than 2 micromol/L for at least 7 days; nitric oxide levels also were lowered. There were no grade 3 or 4 toxicities directly attributable to the drug. Six of 24 phase I to II patients responded to treatment (five partial responses and one complete response; 25% response rate) and also had prolonged survival. CONCLUSION Elimination of all detectable plasma arginine in patients with metastatic melanoma was well tolerated and may be effective in the treatment of this cancer. Further testing of ADI-SS PEG 20,000 mw in a larger population of individuals with metastatic melanoma is warranted.
AuthorsPaolo A Ascierto, Stefania Scala, Giuseppe Castello, Antonio Daponte, Ester Simeone, Alessandro Ottaiano, Gerardo Beneduce, Vincenzo De Rosa, Francesco Izzo, Maria Teresa Melucci, C Mark Ensor, Archie W Prestayko, Frederick W Holtsberg, John S Bomalaski, Mike A Clark, Niramol Savaraj, Lynn G Feun, Theodore F Logan
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 23 Issue 30 Pg. 7660-8 (Oct 20 2005) ISSN: 0732-183X [Print] United States
PMID16234528 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Nitric Oxide
  • Polyethylene Glycols
  • Arginine
  • Hydrolases
  • arginine deiminase
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Arginine (blood)
  • Female
  • Humans
  • Hydrolases (administration & dosage, pharmacokinetics, pharmacology)
  • Italy
  • Male
  • Maximum Tolerated Dose
  • Melanoma (drug therapy, enzymology, genetics)
  • Middle Aged
  • Nitric Oxide (metabolism)
  • Polyethylene Glycols (administration & dosage, pharmacokinetics, pharmacology)
  • Skin Neoplasms (drug therapy, enzymology, secondary)
  • Survival Rate
  • Treatment Outcome
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: